International workshop on immune tolerance induction: Consensus recommendations

Haemophilia

Volumn 13, Issue SUPPL. 1, 2007, Pages 1-22

  DiMichele, D M ^a   Hoots, W K ^b   Pipe, S W ^c   Rivard, G E ^d   Santagostino, E ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Factor IX; Factor VIII; Hemophilia A; Hemophilia B; Immune tolerance induction; Inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESMOPRESSIN ACETATE; DEXAMETHASONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; STEROID; VINCRISTINE; VON WILLEBRAND FACTOR;

ALLERGIC REACTION; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CATHETER INFECTION; CATHETER REMOVAL; CATHETER THROMBOSIS; CD4+ T LYMPHOCYTE; CENTRAL VENOUS CATHETERIZATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GENOTYPE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LEUKEMIA; LOW DRUG DOSE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS;

BLOOD COAGULATION FACTOR INHIBITORS; CATHETERS, INDWELLING; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; EQUIPMENT FAILURE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOSUPPRESSION; INFANT; INFECTION; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT FAILURE;

EID: 34347360724     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01497.x     Document Type: Article

References (149)

1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in haemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
2. Brackmann HH, Wallny T. Immune tolerance: High-dose regimen. In: Rodriguez-Merchan E.C., ed. Inhibitors in Patients with haemophilia. Oxford, England: BlackwePl Science, Ltd, 2002: pp. 45-48.
3. Kessler CM. New perspectives in hemophilia treatment. Hematol Am Soc Hematol Educ Program 2005: 429-35.
4. UK Haemophilia Centre Doctors' Organisation (UKHCDO). The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
5. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
6. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
7. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
8. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
9. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
10. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
11. Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: Results from the NovoSeven emergency -use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
12. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10 (Suppl. 2): 41-5.
13. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor. Blood 2007; 109: 546-51.
14. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547-54.
15. DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10 (Suppl. 4): 140-5.
16. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl. 3): 25-32.
17. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
18. Hay CRM. Inhibitors to factor VIII/IX: Treatment of inhibitors - immune tolerance induction. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Malden, MA: Blackwell Publishing Ltd: 2005; 74-9.
19. DiMichele D. Immune tolerance: Critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12: 81-6.
20. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl. 1): 25-7.
21. Lenk H. The German Registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica 2000; 85: 45-7.
22. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
23. DiMichele DM, Hay CR. The international immune tolerance study: A multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
24. Agency for Health Care Policy and Research. Guidelines on the Use of Colony-stimulating Factors in Haematological Malignancies. Rockville, MD: US Department of Health and Human Services. Agency for Health Care Policy and Research; 1993. AHCPR publication 92-0023.
25. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
26. DiMichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
27. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
28. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
29. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
30. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
31. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
32. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: Final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
33. Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost 2006; 32 (Suppl. 2): 10-4.
34. Lorenzo J, Lopez A, Altisent C, Aznar J. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
35. Koestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120.
36. Astermark J. Overview of inhibitors. Semin Hematol 2006; 43: S3-S7.
37. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
38. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77 (Suppl. 1): 33-7.
39. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: The Spanish Registry. Haemophilia 2001; 7: 154-9.
40. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
41. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': Predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl. 1): 49-54.
42. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
43. Damiano ML, Hutter JJ. Jr Immune tolerance for haemophilia patients with inhibitors: Analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526-32.
44. Rocino A, Papa M, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: Experience at a single institution. Haemophilia 2001; 7: 33-8.
45. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Low-dose immune tolerance therapy: The van creveld model. Vox Sang 1996; 70 (Suppl. 1): 66-7.
46. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
47. Berntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70 (Suppl. 1): 36-41.
48. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird, LE, Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th edn. New York, NY: McGraw-Hill Medical Publishing Division, 2001: 1395.
49. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
50. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994; 71: 703-6.
51. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors -twenty years' 'Bonn protocol'. Vox Sang 1996; 70 (Suppl. 1): 30-5.
52. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
53. DiMichele D, Kroner B. and The ISTH Factor VIII/IX Subcommitee. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. Vox Sang 1999; 77: 31-2.
54. DiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
55. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: A review. Semin Thromb Hemost 2003; 29: 69-76.
56. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
57. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
58. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
59. Rocino A, Salerno E, Capasso F al. Secondary prophylaxis in severe haemophilia A: Results in preventing further joint damage [abstract]. Thromb Haemost 1999; 82: 610. Abstract 1923A.
60. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
61. Barnes C, Rivard GE, Poon MC et al. Canadian multi-institutional survey of immune tolerance therapy (ITT) -experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1-6.
62. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
63. Kreuz W. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
64. Kreuz W, Escuriola-Ettingshausen C, Auerswald G. Immune tolerance induction in haemophilia A patients with inhibitors: The choice of concentrate affecting success. Haematologica 2001; 86 (Suppl. 4): 16-20.
65. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
66. Orsini F, Rothschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
67. Gringeri A, Musso R, Bernasconi S. Immunotolerance induction (ITI) with high purity FVIII/VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: A prospective surveillance. J Thromb Haemost 2005; 3 (Suppl. 1): A207.
68. Mannucci PM, Chediak J, Hanna W et al. and The Alphanate Study Group Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
69. Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinicalk issues. Haematologica 2003; 88 (Suppl. 9): EREP02.
70. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
71. Kasper C. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia: World Federation of Hemophilia, 2004.
72. Berntorp E. Immune tolerance induction: Recombinant vs. human-derived product. Haemophilia 2001; 7: 109-13.
73. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S27-31.
74. Suzuki T, Arai M, Amano K, Kagawa K and Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
75. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
76. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
77. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: Is it of clinical importance ? Haematologica 2003; 88: EREP03.
78. Freedman J, Rand ML, Russell O et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: 1508-13.
79. Knobl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999; 77 (Suppl. 1): 57-64.
80. Rivard GE, St Louis J, Lacroix S, Champagne M and Rock G. Immunoadsorption for coagulation factor inhibitors: A retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711-6.
81. Manco-Johnson MJ, Abshire T, Brown D et al. Initial results of a randomized prospective trial of prophylaxis to prevent joint disease in young children with factor VIII(FVIII) deficiency [abstract]. Blood 2005; 106: Abstract 3.
82. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: The Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
83. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
84. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179-88.
85. Kreuz W, Escuriola-Ettingshausen C, Mentzer D et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 266a. Abstract 1141.
86. Valentino L. FEIBA prophylaxis in hemophilia A patients with inhibitors results in a 95% reduction in bleeding episodes. Bangkok, Thailand: Abstract presented at: 26th World Federation of Hematology Congress; October 17-21, 2004, 2004.
87. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
88. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
89. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
90. Konkle BA, Ebbesen LS, Friedrich U et al. Secondary Prophylactic Treatment with rFVIIa in Patients with Haemophilia A or B and Inhibitors with High Requirements for On-demand Treatment: Analysis of Primary Endpoint and Safety. Vancouver, Canada: Poster presented at: XXVII International Congress of the World Federation of Hemophilia; 21-5 May 2006.
91. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
92. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
93. Kreuz W, Escuriola-Ettingshausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 265a. Abstract 1140.
94. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
95. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003; 9: 573-7.
96. Carcao MD, Connolly BL, Chait P et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 9: 578-83.
97. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
98. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
99. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
100. Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: One haemophilia treatment center experience. Haemophilia 1997; 3: 194-8.
101. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66-70.
102. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003; 9: 50-6.
103. van Dijk K, van Der Bom JG, Bax KN, Van Der Zee DC and Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: Benefits and burden. Haematologica 2004; 89: 189-94.
104. van den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia - a review. Haemophilia 1998; 4: 418-20.
105. Hay CRM, Keegan J, Goldstone J et al. International Immune Tolerance (ITI) Study: Frequency of Central Venous Line Infection and Effect on ITI Outcome. Poster presented at: 27th World Federation of Hematology Congress; 21-25 May 2006; Vancouver, Canada. 2006.
106. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
107. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: A prospective study. Br J Haematol 2003; 123: 502-6.
108. National Institute of Diabetes and Digestive and Kidney Diseases. Vascular Access for Hemodialysis. NIH Publication no. 05-4554. January 2005. Available at: http://www.kidney.niddk.nih.gov/kudiseases/pubs/pdf/ vascularaccess.pdf. (accessed on 17 January 2007).
109. Carcao M, St Louis J, Poon MC et al. Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006;12: 7-18.
110. Collins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12 (Suppl. 6): 94-101.
111. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
112. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
113. Dunkley S, Lindeman R. Successful treatment of a high titre factor VIII inhibitor with rituximab alone [abstract]. J Thromb Haemost 2005; 3 (Suppl. 1): Abstract P631.
114. Escobar M, Kempton C and Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab [abstract]. Blood 2002; 100: 109b abstract 3915.
115. Curry N, Stanworth S, Keeling D. The use of rituximab in two children with allo-antibodies towards factor VIII. Br J Haematol 2006; 133: 214-6.
116. Curtin J, Misra A, Teo J, Webster B, Lammi A. Use of rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia A [abstract]. Haemophilia 2004; 10 (Suppl. 3): 57. Abstract 30.
117. Linde R, Escuriola-Ettinghausen C, Konigs C, Dunsch D, Stoll H. Kreuz W. Rituximab as a new inhibitor elimination agent in high-titer inhibitor patients - a long-term follow-up [abstract]. Haemophilia 2004; 10 (Suppl. 3): 60. Abstract 51.
118. Mateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs. Thromb Haemost 2006; 95: 386-7.
119. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
120. Medeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy [abstract]. Blood 2002; 100: 103b. Abstract 3890.
121. Moschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K. Tzortzatou-Stathopoulou F. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95-9.
122. Pruthi RK, Schmidt KA, Slaby JA, Hook CC, Nichols WL. Rituximab treatment of FVIII inhibitors in congenital hemophilia A (cHA) [abstract]. J Thromb Haemost 2005; 3 (Suppl. 1): Abstract P652.
123. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-22.
124. IITI. International, Randomised, Controlled Trial of Immune-tolerance Induction. Available at: http://www.itistudy.com (accessed on 12 January 2007).
125. Teitel J. Inhibitor economics. Semin Hematol 2006; 43: S14-S17.
126. Mariani G, Kroner B. Immune tolerance in hemophilia and inhibitors: A cost analysis. Transfusion 2000; 40: 495-6.
127. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 2000; 96: 1698-702.
128. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
129. Gringeri A, Mantovani L, Mackensen SV. Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia 2006; 12 (Suppl. 3): 22-9.
130. Wasserman J, Aday LA, Begley CE, Ahn C, Lairson DR. Measuring health state preferences for hemophilia: Development of a disease-specific utility instrument. Haemophilia 2005; 11: 49-57.
131. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
132. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
133. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
134. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
135. d'Oiron R, Volot F, Reynaud J et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors. Semin Hematol 2006; 43: S3-S9.
136. DiMichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119-25.
137. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
138. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S125-8.
139. Warrier I, Ewenstein BM, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
140. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-5.
141. Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54: 201-13.
142. Ewenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6.
143. DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12 (Suppl. 6): 81-86.
144. Wermes C, von Depka Prondzinski M, Welte K, Sykora K.-W. New strategy for the treatment of factor IX inhibitors in severe haemophilia B [abstract]. Blood 2000; 96: 267A. Abstract 1148.
145. Ananyeva NM, Lacroix-Desmazes S, Hauser CA et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109-24.
146. Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12 (Suppl. 6): 30-6.
147. Tarantino M, Ma A, Aledort L. Safety of human plasma-derived clotting factor products and their role in hemostasis in patients with hemophilia: meeting report. Haemophilia (in press).
148. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
149. Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report. Haemophilia 2001; 7: 439-40.